Zobrazeno 1 - 10
of 58
pro vyhledávání: '"A M, Mishriky"'
Publikováno v:
Primary Care Diabetes. 16:471-473
Given the CV benefit noted in the CVOTs, GLP-1RAs and SGLT-2is are given preference in T2DM guidelines. While guidelines do not report potential gender difference, those differences exist. On restricting the CVOTs results to women with increased CV r
Autor:
BASEM M. MISHRIKY, DOYLE M. CUMMINGS, YUANYUAN FU, JACQUIE HALLADAY, WILLIAM S. JONES, ANDREA BOAN, SARA JONES BERKELEY, SHIVAJIRAO P. PATIL, JAMES R. POWELL, ALYSSA ADAMS, WILLIAM IRISH
Publikováno v:
Diabetes. 71
While African Americans (AA) were underrepresented in the SGLT2i CVOT, the results from those trials were generalized to all, regardless of race. Our goal was to evaluate the risk of heart failure hospitalization (hHF) among AA vs. White (Wh) vs. His
Publikováno v:
Primary care. 49(2)
Diabetes-related microvascular complications include diabetic neuropathy (eg, diabetic symmetric polyneuropathy (DSPN), cardiac autonomic neuropathy, gastroparesis, enteropathy, erectile dysfunction, female sexual dysfunction, and hypoglycemia unawar
Autor:
Hesham I Al-Khashan, Fahad S Al Sabaan, Hifa S Al Nasser, Ahmed A Al Buraidi, Ahmed D Al Awad, Ghalib B Horaib, AlJoharah H Al Obaikan, Adel M Mishriky
Publikováno v:
Journal of Family and Community Medicine, Vol 21, Iss 3, Pp 147-153 (2014)
Aim: The aim was to measure the prevalence of smoking and identify its potential predictors among military personnel in Kingdom of Saudi Arabia (KSA). Materials and Methods: This cross-sectional study was carried out among military personnel in the f
Externí odkaz:
https://doaj.org/article/02b9103ca2be4496ac0466c3d9d0583c
Publikováno v:
Diabetes, Obesity and Metabolism. 23:276-280
Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor that has recently been shown to reduce the incidence of reported episodes of atrial fibrillation (AF)/atrial flutter in the DECLARE-TIMI 58 trial. This raises the question regarding
Autor:
Muna R. Mian, Stephanie O. Page, Doyle M. Cummings, Shivajirao P. Patil, Jarrod Uhrig, James R. Powell, Kerry Sewell, Basem M. Mishriky
Publikováno v:
The Journal of Clinical Pharmacology. 60:980-991
Our aim was to explore whether the baseline hemoglobin A1c or the dose of sodium glucose cotransporter-2 inhibitor (SGLT-2i) chosen better predicted the efficacy of SGLT-2i versus dipeptidyl peptidase-4 inhibitor (DPP-4i) in type 2 diabetes. We searc
Autor:
Hesham I Al-Khashan, Naseem A Almulla, Siddig A. A. Galil, Ashraf A Rabbulnabi, Adel M Mishriky
Publikováno v:
Journal of Family and Community Medicine, Vol 19, Iss 3, Pp 172-177 (2012)
Background and Aim: Health reforms that tend to increase the participation of clients in decision-making requires them to be health-literate; hence, the importance of health education. However, not much research has been done to investigate the diffe
Externí odkaz:
https://doaj.org/article/de46cbd0f4f445bcae54ff7900881655
Autor:
Basem M Mishriky, Doyle M Cummings, Yuanyuan Fu, Jacquie Halladay, Schuyler Jones, Andrea Boan, Sara Jones, Shivajirao Patil, James Powell, Alyssa Adams, William Irish
Publikováno v:
Journal of the Endocrine Society. 6:A282-A282
The results from the SGLT-2 inhibitors cardiovascular outcome trials were generalized to all, despite that non-Hispanic Black (hereafter, "Black") participants were underrepresented. Our goal was to evaluate, among patients with type 2 diabetes, the
Autor:
Giustino Varrassi, Joseph V. Pergolizzi, Ahmed Mokhtar Fathy Ibrahim, John F. Peppin, Adel M. Mishriky, Antonella Paladini, Amany E. Ayad, Martina Rekatsina, Waleed A. M. Al-Taher, Ossama Hamdy Salman, Ivan Urits, Omar Viswanath
Publikováno v:
Pain and Therapy
Publikováno v:
Postgraduate Medicine. 131:376-382
Objective: To investigate the relationship between insulin use and clinical outcomes in patients with type 2 diabetes stratified by level of insulin resistance (IR).Methods: Cross sectional...